AbbVie’s new 6-month 45mg LUPRON DEPOT has received Health Canada approval for treating advanced prostate cancer. This hormonal medication is now available in four dosing options and is also approved for conditions like endometriosis and uterine fibroids. LUPRON DEPOT, a synthetic gonadotropin-releasing hormone analog, was first approved in 1989 for advanced prostate cancer. For more health news, visit rttnews.com.

Read more at Nasdaq: AbbVie: New 6-month 45mg LUPRON DEPOT Strength Receives Health Canada Approval